Web-based Clinical Trial Against Marburg Virus Epidemic in Angola
Apr 29, 2005 - 8:08:00 PM
|
|
|
"Our positive experience so far with West Nile virus encephalitis gives us hope that our approach will be successful against other lethal viruses like Marburg virus. We're grateful to Angola for allowing us to try to help during the current awful epidemic."
|
By GenoMed, Inc.,
[RxPG] GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that it has launched a free clinical trial to combat the current Marburg virus epidemic in Angola.
Marburg virus causes a hemorrhagic fever which is fatal in 80% of cases. The current epidemic, the largest in history, began in the northern province of Uige in Angola in early March. It has since spread throughout much of Angola. So far, over 240 people have died, many of them children, and another 264 people are currently infected.
Marburg virus is considered a prime candidate for use by viral bioterrorists.
GenoMed believes it has a broad-spectrum viral antidote, which it has been testing successfully against West Nile virus for the past two summers. It should work equally well against influenza, avian influenza, SARS, respiratory syncytial virus (RSV) in children, and the common cold. It may also be effective against HIV and tuberculosis (Tb). Tb, of course, is caused by the tubercle bacillus, a kind of bacteria.
Said Dr. David Moskowitz, Chief Medical & Executive Officer for GenoMed, "Our positive experience so far with West Nile virus encephalitis gives us hope that our approach will be successful against other lethal viruses like Marburg virus. We're grateful to Angola for allowing us to try to help during the current awful epidemic."
Dr. Moskowitz went on to say, "The Internet now makes it possible for anybody to enroll in our free clinical trial at any time of day or night anywhere in the world, simply by going to our website and clicking on the link for the trial. People will have to enter their email address so that we can follow up with them and eventually publish our results. In return for their email address, they'll be able to download the documents they'll need to show their physician in order to get started immediately on our trial. A family member could easily do this for a child who is sick. The drugs we use are available in every drug store around the world."
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Marburg Newsletter
|
|
|
|
Additional information about the news article
|
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. In autoimmune diseases, a person's own immune system causes the disease. Like most viruses, Marburg virus appears to hurt patients by overstimulating the immune system, and cannot cause damage by itself.
For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-983-9933, email: [email protected], or visit GenoMed at www.genomed.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether GenoMed's approach will lower mortality from Marburg virus; (b) whether GenoMed's server will hold up to international demand; (c) whether we will have sufficient financing to conduct our research and development; and (d) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
